ArticleeLife2021
Open access · goldAbstract read
In one paragraph
Article in eLife, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
111citing papers in PubMed, 3 pooled it
25.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
111 citing papers in PubMed, 3 syntheses or guidelines pooled it, 170 citations in OpenAlex.
- Spatio-temporal trends of artemisinin-based combination therapy efficacy from 2010 to 2024 in sub-Saharan Africa: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Mapping Antimalarial Drug Resistance in Mozambique: A Systematic Review ofInternational journal of molecular sciences · 2024Pooled it
- Identification of Co-Existing Mutations and Gene Expression Trends Associated With K13-Mediated Artemisinin Resistance inFrontiers in genetics · 2022Pooled it
- Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial.The Lancet. Infectious diseases · 2022Trial
- Genomic profiling of drug resistance markers in Plasmodium falciparum samples from the Democratic Republic of the Congo (2017) and Tanzania (2020-2021).The Journal of antimicrobial chemotherapy · 2026Article
- Dual plasmepsin IX and X inhibitors are refractory to development of resistance.PLoS pathogens · 2026Article
- Serratia marcescens and Enterobacter cloacae exhibit differential population dynamics in Anopheles gambiae s.l after sugar and blood feeding.Malaria journal · 2026Article
- Functional assessment of prevalentmBio · 2026Article
- Double Mutations inbioRxiv : the preprint server for biology · 2026Article
- Functional validation of thebioRxiv : the preprint server for biology · 2026Article
- Article
- Single-cell transcriptional changes of artemisinin-sensitive K13Frontiers in cellular and infection microbiology · 2026Article
- Towards an evolutionary baseline model ofbioRxiv : the preprint server for biology · 2025Article
- Recrudescent severe malaria due to Plasmodium falciparum following treatment in a Taiwanese patient: a case report.Malaria journal · 2025Article
- Acetyl-CoA synthetase mutations affect the susceptibility ofMicrobiology spectrum · 2025Article
- Review
- Mapping Plasmodium falciparum mutations in Africa: A critical review of emerging drug resistance and implications for malaria control.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2025Review
- A recombinant expression system for thebioRxiv : the preprint server for biology · 2025Article
- Tafenoquine Disrupts Intraerythrocytic Stages of Malaria Parasites by Inhibiting Nonclassical Pathways of β-Hematin Nucleation and Growth.Biochemistry · 2025Article
- Prevalence of Plasmodium falciparum parasites harbouring chloroquine-resistant but not artemisinin-resistant alleles in Busia County, Western Kenya.Malaria journal · 2025Article
51 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 16 institutions in 14 countries.
Barbara H StokesDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, United States.ORCID 0000-0001-9519-487X
Satish K DhingraDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, United States.
Kelly RubianoDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, United States.ORCID 0000-0002-4149-4030
Sachel MokDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, United States.ORCID 0000-0002-9605-0154
Judith StraimerDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, United States.
Nina F GnädigDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, United States.
Ioanna DeniDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, United States.ORCID 0000-0002-5266-8243
Kyra A SchindlerDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, United States.
Jade R BathDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, United States.
Kurt E WardDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, United States.ORCID 0000-0002-3614-436X
Josefine StriepenDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, United States.
Tomas YeoDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, United States.ORCID 0000-0003-2923-6060
Leila S RossDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, United States.
Eric LegrandMalaria Genetics and Resistance Unit, Institut Pasteur, INSERM U1201, CNRS ERL9195, Paris, France.
Frédéric ArieyInstitut Cochin, INSERM U1016, Université Paris Descartes, Paris, France.
Clark H CunninghamDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, United States.
Issa M SouleymaneProgramme National de Lutte Contre le Paludisme au Tchad, Ndjamena, Chad.
Adama GansanéCentre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso.
Romaric Nzoumbou-BokoLaboratoire de Parasitologie, Institut Pasteur de Bangui, Bangui, Central African Republic.
Claudette NdayikundaUniversity Teaching Hospital of Kamenge, Bujumbura, Burundi.
Abdunoor M KabanywanyiIfakara Health Institute, Dar es Salaam, United Republic of Tanzania.ORCID 0000-0002-2980-0429
Aline UwimanaMalaria and Other Parasitic Diseases Division, Rwanda Biomedical Centre, Kigali, Rwanda.
Samuel J SmithNational Malaria Control Program, Freetown, Sierra Leone.
Olimatou KolleyNational Malaria Control Program, Banjul, Gambia.
Mathieu NdoungaProgramme National de Lutte Contre le Paludisme, Brazzaville, Democratic Republic of the Congo.
Marian WarsameSchool of Public Health and Community Medicine, University of Gothenburg, Gothenburg, Sweden.
Rithea LeangNational Center for Parasitology, Entomology & Malaria Control, Phnom Penh, Cambodia.
François NostenShoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand.ORCID 0000-0002-7951-0745
Timothy Jc AndersonTexas Biomedical Research Institute, San Antonio, United States.
Philip J RosenthalDepartment of Medicine, University of California, San Francisco, San Francisco, United States.
Didier MénardMalaria Genetics and Resistance Unit, Institut Pasteur, INSERM U1201, CNRS ERL9195, Paris, France.
David A FidockDivision of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, United States.ORCID 0000-0001-6753-8938
Columbia University Irving Medical Center · USCentre National de la Recherche Scientifique · FRCambodia National Malaria Center · KHCentre National de Recherche et de Formation sur le Paludisme · BFIfakara Health Institute · TZInserm · FRInstitut Pasteur de Bangui · CFMahidol University · THProgramme National Multisectoriel de Lutte contre le sida · CDRwanda Biomedical Center · RWSierra Leone Urban Research Centre · SLTexas Biomedical Research Institute · USUniversity of California, San Francisco · USUniversity of Gothenburg · SEUniversity of N'Djamena · TDUniversity of North Carolina at Chapel Hill · US
Funding
MEDICAL SCIENTIST TRAINING PROGRAMT32GM008719 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DARVILLE, TONI, DESHMUKH, MOHANISH P · 1999 to 2023
$15.1MTRAINING GRANTS IN ENVIROMENTAL TOXICOLOGYT32ES007020 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ESSIGMANN, JOHN M · 1985 to 2024
$13.1MResistance of Malaria Parasites to Artemisinin-Based TherapiesR01AI075045 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSENTHAL, PHILIP JON · 2009 to 2024
$8.4MMapping Drug Resistance Genes in Plasmodium falciparumR37AI048071 · NIAID · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI ANDERSON, TIM J · 2012 to 2021
$7.9MDefining P. falciparum resistance to artemisinin-based combination therapiesR01AI109023 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FIDOCK, DAVID A · 2014 to 2025
$4.4MVariation in Resistance and Fitness to Artemisinins in African MalariaR01AI121558 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JULIANO, JONATHAN J · 2016 to 2020
$3.3MColumbia University Graduate Training Program in Microbiology and ImmunologyT32AI106711 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Nicholas Arpaia, Uttiya Basu · 2014 to 2026
$2.1MNIAID NIH HHS R01 AI075045NIAID NIH HHS R01 AI109023NIAID NIH HHS R01 AI121558NIAID NIH HHS R37 AI048071NIAID NIH HHS T32 AI106711NIEHS NIH HHS T32 ES007020NIGMS NIH HHS T32 GM008719Wellcome Trust 106698
Abstract
The emergence of mutant K13-mediated artemisinin (ART) resistance in
Indexed as
MutationAfricaAntimalarialsArtemisininsAsiaCambodiaDrug ResistanceHumansMalaria, FalciparumMolecular EpidemiologyPlasmodium falciparumProtozoan ProteinsAntimalarialsartemisininArtemisininsProtozoan Proteinsartemisinin resistanceCRISPR/Cas9epidemiologyfitnessglobal healthinfectious diseasemalariamicrobiologyP. falciparumPlasmodium falciparumring-stage survival
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.